The Food and Drug Administration has cleared the Abbott influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing.
Both assays are available on the ID NOW™ platform and have been granted a Clinical Laboratory Improvement Amendments certificate of waiver. The enhanced assay offers the fastest point-of-care molecular detection and differentiation of influenza A and B virus available – in 13 minutes or less, with early call out of positive results in as little as five minutes, Abbott said.
“These Influenza A & B 2 and Strep A 2 assays combine speed with efficacy for rapid delivery of molecular results, further driving value for healthcare systems where time equals money,” said Sharon Bracken, senior vice president, Rapid Diagnostics at Abbott. “By delivering fast and accurate molecular results at the point of care, these tests provide physicians with the confidence to give the right diagnosis and the ability to prescribe the right treatment earlier.”
